Proton MR Spectroscopy Provides Relevant Prognostic Information in High-Grade Astrocytomas

References

1. 1.↵
   1. Louis DN,
   2. Ohgaki H,
   3. Wiestler OD,
   4. et al

   . The 2007 WHO Classification of Tumors of the Central Nervous System. Lyon, France: IARC Press; 2007
2. 2.↵
   CBTRUS, The Central Brain Tumor Registry of the United States. 2008 Statistical Report: Primary Brain Tumors in the United States, 1998–2002. http://www.cbtrus.org/reports/2007–2008/2007report.pdf. Accessed July 7, 2009
3. 3.↵
   1. Stupp R,
   2. Mason WP,
   3. van den Bent MJ,
   4. et al

   . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Vredenburgh JJ,
   2. Desjardins A,
   3. Herndon JE II.,
   4. et al

   . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–59

   Abstract/FREE Full Text
5. 5.↵
   1. Jackson RJ,
   2. Fuller GN,
   3. Abi-Said D,
   4. et al

   . Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001;3:193–200

   Abstract/FREE Full Text
6. 6.↵
   1. Prayson RA,
   2. Agamanolis DP,
   3. Cohen ML,
   4. et al

   . Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. J Neurol Sci 2000;175:33–39

   CrossRefPubMed
7. 7.↵
   1. Kros JM,
   2. Gorlia T,
   3. Kouwenhoven MC,
   4. et al

   . Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007;66:545–51

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Cairncross JG,
   2. Ueki K,
   3. Zlatescu MC,
   4. et al

   . Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473–79

   Abstract/FREE Full Text
9. 9.↵
   1. Curran WJ,
   2. Scott CB,
   3. Horton J,
   4. et al

   . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704–10

   Abstract/FREE Full Text
10. 10.↵
    1. Gorlia T,
    2. van den Bent MJ,
    3. Hegi ME,
    4. et al

    . Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE. 3. Lancet Oncol 2008;9:29–38. Epub 2007 Dec 21

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Wen PY,
    2. Kesari S

    . Malignant gliomas in adults. N Eng J Med 2008;359:492–507

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Murakami R,
    2. Sugahara T,
    3. Nakamura H,
    4. et al

    . Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007;243:493–99

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Pope WB,
    2. Kim HJ,
    3. Huo J,
    4. et al

    . Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182–89

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Law M,
    2. Young RJ,
    3. Babb JS,
    4. et al

    . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Oh J,
    2. Henry RG,
    3. Pirzkall A,
    4. et al

    . Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004;19:546–54

    CrossRefPubMed
16. 16.↵
    1. Kuztnesov YE,
    2. Caramanos MA,
    3. Antel SB,
    4. et al

    . Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery 2003;53:565–76

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Li X,
    2. Jin H,
    3. Lu Y,
    4. et al

    . Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004;17:10–20

    CrossRefPubMed
18. 18.↵
    1. van den Boogaart A

    . Quantitative data analysis of in vivo MRS data sets. Magn Reson Chem 1997;35:S146–52

    CrossRefWeb of Science
19. 19.↵
    1. Tate AR,
    2. Underwood J,
    3. Acosta D,
    4. et al

    . Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 2006;19:411–34

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Tate AR,
    2. Griffiths JR,
    3. Martínez-Pérez I,
    4. et al

    . Towards a method for automated classification of 1H MRS spectra from brain tumours. NMR Biomed 1998;11:177–91

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Scott CB,
    2. Scarantino C,
    3. Urtasun R,
    4. et al

    . Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90–06. Int J Radiat Oncol Biol Phys 1998;40:51–55

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Majós C,
    2. Aguilera C,
    3. Alonso J,
    4. et al

    . Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol 2009;30:544–51

    Abstract/FREE Full Text
23. 23.↵
    1. Kim SH,
    2. Chang KH,
    3. Song IC,
    4. et al

    . Brain abscess and brain tumor: discrimination with in vivo H-1 MR spectroscopy. Radiology 1997;204:239–45

    PubMedWeb of Science
24. 24.↵
    1. Negendank WG,
    2. Sauter R,
    3. Brown TR,
    4. et al

    . Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996;84:449–58

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Castillo M,
    2. Kwock L

    . Proton MR spectroscopy of common brain tumors. Neuroimaging Clin North Am 1998;8:733–52
26. 26.↵
    1. Bruhn H,
    2. Michaelis T,
    3. Merboldt KD,
    4. et al

    . Monitoring cerebral glucose in diabetics by proton MRS. Lancet 1991;337:745–46

    PubMedWeb of Science
27. 27.↵
    1. Moreno-Torres A,
    2. Martínez-Pérez I,
    3. Baquero M,
    4. et al

    . Taurine detection by proton magnetic resonance spectroscopy in medulloblastoma: contribution to noninvasive differential diagnosis with cerebellar astrocytoma. Neurosurgery 2004;55:824–29

    PubMedWeb of Science
28. 28.↵
    1. Righi V,
    2. Roda JM,
    3. Paz J,
    4. et al

    . 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed 2009;22:629–37

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Grand S,
    2. Passaro G,
    3. Ziegler A,
    4. et al

    . Necrotic tumor versus brain abscess: importance of amino acids detected at 1H MR spectroscopy-initial results. Radiology 1999;213:785–93

    CrossRefPubMedWeb of Science